Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 AlteredExpression disease BEFREE The mixed expression of BRAF under varying levels of differentiation may explain, in part, the contradictory studies regarding the impact of BRAF mutations on patient prognosis and also indicates a complex genomic signature for dedifferentiated thyroid cancer. 31229486 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. 30398411 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. 31322645 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers. 31529211 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE This includes frequently reported gene fusions such as CCDC6/RET (PTC1), PRKAR1A/RET (PTC2) and ETV6/NTRK3 , and gene fusions that are less common in thyroid cancer (TPM3/NTRK1, EML4/ALK and EML4/NTRK3). 30668525 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines. 30531837 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E mutant thyroid cancer specimens, thereby promoting glycolysis. 30768848 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE Combination strategies involving immune checkpoint inhibitors (ICIs) with tyrosine kinase (TK) or serine/threonine protein kinase B-raf (BRAF) inhibitors are showing considerable promise in the treatment of advanced thyroid cancer. 31412566 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE Patients with RAIR, BRAF mutant thyroid cancer. 30256977 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE BRAFi inhibited ERK signaling in BRAF<sup>V600E</sup> mutants, but not BRAF wild-type thyroid cancer cell lines. 31097454 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions. 30481266 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. 31540406 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 AlteredExpression disease BEFREE BRAF-targeted paired box gene-8 (PAX8), a thyroid-specific transcription factor, generally dysregulated in BRAF-mutated thyroid cancer. 30760304 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 AlteredExpression disease BEFREE In conclusion, the results of the current study suggest that BRAF<sup>V600E</sup>-induced KRT19 expression may promote thyroid cancer metastasis via EMT. 31289571 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Several drugs targeting RET have been approved by the FDA for the treatment of cancer: (i) cabozantinib and vandetanib for medullary thyroid carcinomas and (ii) lenvatinib and sorafenib for differentiated thyroid cancers. 29284153 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. 29515777 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE In the present study, we investigated whether the oncogenic RET mutants RET2A (C634R) and RET2B (M918T) were regulated by LRIG1, and the possible effects of LRIG1 expression in thyroid cancer were investigated in three different clinical cohorts and in a RET2B-driven mouse model of MTC. 29436694 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE Our results demonstrate a strong clinical potential for the combination of the Bortezomib and the BRAF inhibitor Vemurafenib as an efficient therapeutic approach for the treatment of TC. 29269566 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE TERT promoter mutations were likely to occur in BRAF V600E positive TC. 30024548 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker disease BEFREE Therefore, we examined the efficacy of the combination therapy across a panel of thyroid cancer cell lines representing common oncogenic drivers (BRAF, RAS, and PIK3CA). 29487290 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE However, the response to vemurafenib is limited in BRAF-mutant thyroid cancer. 29737325 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE This study explores the possibility of building AI models without precise pixel-level annotation in prediction of the tumor size, extrathyroidal extension, lymph node metastasis, cancer stage and BRAF mutation in thyroid cancer diagnosis, providing the patients' background information, histopathological and immunohistochemical tissue images. 29293907 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers. 29134959 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE These results confirm that PATZ1 downregulation has a critical role in thyroid carcinogenesis, showing that it cooperates with RET/PTC1 in thyroid cancer progression. 29584698 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation disease BEFREE Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. 30036146 2018